<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525484</url>
  </required_header>
  <id_info>
    <org_study_id>GP29830</org_study_id>
    <nct_id>NCT02525484</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants</brief_title>
  <official_title>A Phase I, Open-Label, Randomized, Four-Treatment Period, Four-Sequence, Single-Dose, Crossover, Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a Phase I, open-label, randomized, four-treatment period, four-sequence, single-dose,&#xD;
      crossover pharmacokinetic study to determine the bioequivalence of pirfenidone after&#xD;
      administration of tablet and capsule dosage forms under both fed and fasted conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Pirfenidone</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) from Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) of Pirfenidone</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from Time Zero to Infinity (AUC[0-inf]) of Pirfenidone</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of AUC(0-t) to AUC(0-inf) of Pirfenidone</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant of Pirfenidone</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-Life (t1/2) of Pirfenidone</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Plasma Concentration of Pirfenidone</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Pirfenidone ACBD treatment sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given 801 milligrams (mg) single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 1 and in fasted state (treatment C) on Day 4, 801-mg tablet in fed state (treatment B) on Day 7 and in fasted state (treatment D) on Day 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pirfenidone BADC treatment sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fed state (treatment B) on Day 1, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 4, 801-mg tablet in fasted state (treatment D) on Day 7 and capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pirfenidone CDAB treatment sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 1, 801-mg tablet in fasted state (treatment D) on Day 4, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 7 and 801-mg tablet in fed state (treatment B) on Day 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pirfenidone DBCA treatment sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fasted state (treatment D) on Day 1 and in fed state (treatment C) on Day 4, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 7 and in fed state (treatment A) on Day 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.</description>
    <arm_group_label>Pirfenidone ACBD treatment sequence</arm_group_label>
    <arm_group_label>Pirfenidone BADC treatment sequence</arm_group_label>
    <arm_group_label>Pirfenidone CDAB treatment sequence</arm_group_label>
    <arm_group_label>Pirfenidone DBCA treatment sequence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants between 18 and 55 years of age, inclusive, at the time of screening&#xD;
&#xD;
          -  Participants of body mass index of 18.5-30.0 kilograms per square meter (kg/m^2),&#xD;
             inclusive&#xD;
&#xD;
          -  Participants of reproductive potential must be willing to use reliable contraceptive&#xD;
             methods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with significant medical history or unstable hepatic, pulmonary,&#xD;
             metabolic, neurologic, cardiovascular, gastrointestinal, hematologic, or psychiatric&#xD;
             systems, in the opinion of the investigator that may alter the absorption, metabolism,&#xD;
             or elimination of study drug&#xD;
&#xD;
          -  Participants with calculated creatinine clearance rate less than (&lt;) 30 milliliters&#xD;
             per minute (mL/min) (calculated using the Cockcroft-Gault equation) at screening&#xD;
&#xD;
          -  Participants with any use of, or intent to use, medications, including prescription,&#xD;
             over-the-counter, herbal preparations, or vitamin/mineral supplementation other than&#xD;
             study medications from 14 days before screening through the follow-up telephone call&#xD;
             (except for contraception purpose)&#xD;
&#xD;
          -  Participants who have received fluvoxamine therapy within 28 days before screening&#xD;
&#xD;
          -  Participants who have received any medications known to chronically alter drug&#xD;
             absorption, metabolism, or elimination processes within 28 days of screening, or&#xD;
             participants who are taking drugs known to affect liver function, in the opinion of&#xD;
             the Sponsor or investigator&#xD;
&#xD;
          -  Participants who have taken investigative drug and/or device in another clinical study&#xD;
             within 28 days or within the investigational drug 5 half-lives, whichever is longer,&#xD;
             before screening&#xD;
&#xD;
          -  Participants previously dosed in any pirfenidone clinical study&#xD;
&#xD;
          -  Participants with any hypersensitivity or idiosyncratic reaction to pirfenidone or the&#xD;
             constituents of pirfenidone&#xD;
&#xD;
          -  Participants with any elevation of liver test results (alanine aminotransferase [ALT],&#xD;
             aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT], direct bilirubin,&#xD;
             or alkaline phosphatase above the upper limit of normal)&#xD;
&#xD;
          -  Participants with the following hemoglobin levels at screening: males &lt; 13.5 grams per&#xD;
             deciliter (g/dL), females &lt; 11.5 g/dL&#xD;
&#xD;
          -  Females with a positive serum pregnancy test or who are breastfeeding&#xD;
&#xD;
          -  Participants who are seropositive for hepatitis B surface antigen, hepatitis C virus&#xD;
             antibodies, or human immunodeficiency (HIV) antibodies at screening&#xD;
&#xD;
          -  Participants who have a clinically significant abnormal electrocardiogram (ECG) at&#xD;
             screening or a Fridericia corrected QT interval (QTcF) greater than (&gt;) 500&#xD;
             milliseconds (ms) at screening&#xD;
&#xD;
          -  Participants with a plasma donation within 28 days before screening or with a donation&#xD;
             of blood or blood products or significant blood loss within 56 days before screening&#xD;
&#xD;
          -  Participants with poor venous access&#xD;
&#xD;
          -  Participants who have used cigarettes (including vapor cigarettes), cigars, and&#xD;
             nicotine-containing products within 3 months before screening or plan to use them&#xD;
             through completion of the follow-up telephone call&#xD;
&#xD;
          -  Participants with a history of alcoholism or drug abuse, per discretion of the&#xD;
             investigator, within 2 years of screening or a positive qualitative drug screen for&#xD;
             drugs of abuse at screening or Day -1&#xD;
&#xD;
          -  Participants who have not withheld alcoholic beverages/alcohol-containing products or&#xD;
             caffeinated beverages/caffeine- or xanthine-containing products at least 72 hours&#xD;
             before first study dose administration or who plan to consume them during the study or&#xD;
             a positive qualitative drug screen for alcohol at screening or Day -1&#xD;
&#xD;
          -  Participants with an abnormal diet (as determined by the investigator) within the 28&#xD;
             days before first study dose administration&#xD;
&#xD;
          -  Participants who have not withheld consuming cruciferous vegetables (broccoli, kale,&#xD;
             Brussels sprouts), grapefruit or grapefruit juice, or chargrilled meat 48 hours before&#xD;
             dosing or who plan to consume them during the study&#xD;
&#xD;
          -  Participants who cannot refrain from strenuous exercise from 48 hours before first&#xD;
             study dose administration through completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>32953</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>August 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

